Compugen (CGEN) Income from Continuing Operations (2009 - 2026)
Compugen (CGEN) reported Income from Continuing Operations of 7659000.0 for Q1 2026, up 7.59% on a YoY basis from 7119000.0 in Q1 2025, and down 86.5% sequentially from 56737000.0 in Q4 2025.
Compugen (CGEN) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Compugen (CGEN) has 18 years of Income from Continuing Operations data on file, last reported at 7659000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 7.59% year-over-year to 7659000.0; the trailing twelve-month figure through Mar 2026 stood at 35883000.0 (up 772.34% YoY), and the FY2025 full-year result was 35343000.0, up 348.35% from the prior year.
- Income from Continuing Operations fell to 7659000.0 in Q1 2026, from 56737000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 56737000.0 in Q4 2025 to a low of 28000000.0 in Q2 2023.
- A 5-year average of 1352647.06 and a median of 3092000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 198.03% in 2023 and jumped 1027.53% in 2025, its largest moves.
- Tracing CGEN's Income from Continuing Operations over 5 years: stood at 3092000.0 in 2022, then jumped by 414.13% to 9713000.0 in 2023, then sank by 162.98% to 6117000.0 in 2024, then jumped by 1027.53% to 56737000.0 in 2025, then plunged by 86.5% to 7659000.0 in 2026.
- Business Quant data shows CGEN's Income from Continuing Operations at 7659000.0 in Q1 2026, 56737000.0 in Q4 2025, and 6899000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Compugen | 215.59 Mn | 123.84 Mn | 352,000.00 | 7.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.66 Mn |
| Dec 31, 2025 | 56.74 Mn |
| Sep 30, 2025 | -6.90 Mn |
| Jun 30, 2025 | -21.61 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | -6.12 Mn |
| Sep 30, 2024 | 10.28 Mn |
| Jun 30, 2024 | -16.62 Mn |
| Mar 31, 2024 | 7.26 Mn |
| Dec 31, 2023 | 9.71 Mn |
| Sep 30, 2023 | -9.85 Mn |
| Jun 30, 2023 | -28.00 Mn |
| Mar 31, 2023 | 9.31 Mn |
| Dec 31, 2022 | -3.09 Mn |
| Sep 30, 2022 | -11.75 Mn |
| Jun 30, 2022 | 28.56 Mn |
| Mar 31, 2022 | -9.71 Mn |
| Dec 31, 2021 | -8.65 Mn |
| Sep 30, 2021 | -8.18 Mn |
| Jun 30, 2021 | -9.50 Mn |